Oragenics Inc
$ 0.66
-3.83%
14 Apr - close price
- Market Cap 2,953,300 USD
- Current Price $ 0.66
- High / Low $ 0.69 / 0.63
- Stock P/E N/A
- Book Value 1.94
- EPS -4.56
- Next Earning Report 2026-05-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.01 %
- ROE -2.44 %
- 52 Week High 9.60
- 52 Week Low 0.50
About
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company is headquartered in Tampa, Florida.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-03-27 | 2024-11-07 | 2024-08-09 | 2024-05-15 | 2024-03-29 | 2023-11-09 | 2023-08-11 | 2023-04-17 | 2023-03-27 |
| Reported EPS | -1.96 | -3.1 | -3.65 | -0.2664 | -0.3773 | -0.509 | -0.701 | -4.1378 | -0.8543 | -1.5066 | -0.15 | -1.1101 |
| Estimated EPS | 0 | 0 | None | None | None | None | None | None | None | -3 | -2.4 | -2.4 |
| Surprise | -1.96 | -3.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4934 | 2.25 | 1.2899 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | 49.78% | 93.75% | 53.7458% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OGEN
2026-04-13 15:38:57
Oragenics (OGEN) has commenced dosing the first patient in its Phase IIa clinical trial for ONP-002, a drug targeting concussion and mild traumatic brain injury, at Mackay Base Hospital in Australia. This rapid enrollment, with additional sites planned, highlights strong trial momentum and significant clinical demand as there are currently no FDA-approved pharmacological therapies for this condition. While Oragenics aims to be a first-mover in the multi-billion-dollar global concussion market, TipRanks' AI Analyst, Spark, rates OGEN as an "Underperform" due to financial distress, unprofitability, and weak stock momentum.
2026-04-13 14:38:57
Oragenics has dosed its first patient in a Phase IIa clinical trial for ONP-002, a potential first-in-class pharmacological treatment for mild traumatic brain injury (concussion), in Australia. This marks a significant step towards addressing the unmet medical need for concussion, a condition with no FDA-approved drug therapies. The company aims to submit an investigational new drug (IND) application to the FDA by Q4 2026, leveraging robust Phase 1 safety data and a proprietary intranasal delivery method for ONP-002.
2026-04-13 12:38:57
Oragenics has dosed the first patient in its Phase IIa trial for ONP-002, a neuroprotective candidate for concussion and mild Traumatic Brain Injury (TBI). The trial, which will enroll 40 patients, aims to assess the drug's safety, tolerability, and neurocognitive outcomes. Oragenics anticipates using this data to support a Q4 2026 IND submission to the FDA for subsequent U.S. trials.
2026-04-13 12:38:57
Oragenics, Inc. has dosed its first patient in a Phase IIa clinical trial for ONP-002, a lead candidate for mild traumatic brain injury (mTBI) and concussion. The trial began quickly at Mackay Hospital in Australia after site activation, highlighting the urgent unmet medical need for a pharmacological treatment for concussion. ONP-002 is an intranasal neurosteroid designed to address the underlying biology of brain injury, moving beyond symptom management, with a global concussion market projected to reach over $9 billion by 2030.
2026-04-13 12:38:57
Oragenics (NYSE: OGEN) has started patient dosing in its Phase IIa clinical trial for ONP-002, a potential first-in-class treatment for concussion/mild traumatic brain injury (mTBI). The first patient was dosed at Mackay Hospital in Australia shortly after site activation, highlighting the urgent unmet medical need as there are currently no FDA-approved pharmacological treatments for concussion. The randomized, placebo-controlled study will evaluate 40 patients, aiming to support an Investigational New Drug (IND) application with the FDA targeting Q4 2026 for subsequent U.S. trials.
2026-04-11 06:39:58
This article provides an updated overview of Oragenics' (OGEN) short interest and short float as of March 31, 2026. The data indicates that 720,353 shares, or 17.47% of the public float, were sold short, representing a 9.14% decrease since the previous report. The short interest ratio is 5.5 days to cover, suggesting a moderate level of pessimism among investors regarding the stock.
